Skip to Main Content

Paper Details

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
J Clin Oncol
11
2023
Anti-GD2 Antibody, Dinutuximab Beta, GvHD, Haploidentical Stem-Cell Transplantation, Interleukin 2, NB, Patients, Relapsed Neuroblastoma, T, T-/B-cell-depleted haplo, acute graft-versus-host-disease, anti-GD2 antibody dinutuximab beta, chronic GvHD, donor-derived effector cells, graft, haploidentical stem cells, natural killer cells, neuroblastoma, patients, rHR-, relapsed high-risk neuroblastoma, scIL2
Author NameAffiliation
Ruth LadensteinSt Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna
Ruth LadensteinMedical University of Vienna
Peter F AmbrosChildren's Cancer Research Institute, Medical University of Vienna
Johannes H SchulteCharite-Universitaetsmedizin Berlin
Angelika EggertCharite-Universitaetsmedizin Berlin
  • 1 - 5

Datasets

Release 1.2